Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDAM: Dual Antihypertensive Regimens in Patients After PCI
NCT07683585Recruiting
- Sponsor
- National Medical Research Center for Therapy and Preventive Medicine
- Start
- Apr 2026
- Primary completion
- Jul 2026
- Countries
- 1
01
Overview
Randomised, open-label trial of losartan, hydrochlorothiazide, amlodipine and azilsartan in hypertension (HTN) and coronary artery disease (CAD) (2 arms), sponsored by National Medical Research Center for Therapy and Preventive Medicine. Primary endpoint: Change in office systolic and diastolic blood pressure at 12 weeks. Started Apr 2026; status: recruiting.
02
Drugs
losartanhydrochlorothiazideamlodipineazilsartan
03
Conditions
hypertension (HTN)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07683585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07683585.